Mechanistically, both in vitro and in vivo outcomes showed that the co-treatment significantly decreased ALDH1 levels (35–47%, depending on the chemotherapeutic agent) in MCF-7 and MDA-MB-231 cells and tumor tissues, suggesting the targeting of BCSCs by the combination, which resulted in necrosis and tumor growth inhibition [18]. Here, ALDH1A1 is linked to neoplasm.